Health News

of 51
  • Health News Main
Filter News By:
3D Body Maps

Use 3D controls to rotate and explore 10 body areas and 40+ body systems.

View 3D Maps »

ER trips for kids' pain and coughs often end with codeine

By Andrew M. Seaman NEW YORK (Reuters Health) - Despite recommendations against the use of codeine in children, a new study found many emergency room doctors still give the potentially dangerous opioid to kids, such as for pain and coughs. While researchers found that codeine prescriptions for children in U.S. emergency rooms decreased slightly from 2001 to 2010, between about 559,000 and 877,000 kids were still receiving the drug in that setting each year. "My colleague and I felt like this was an important question to look at to get a sense of how often it's being used in the U.S. and to heighten awareness of the issue," Dr. Sunitha Kaiser told Reuters Health. Kaiser is the study's lead author from the University of California, San Francisco.  More »

Wall Street opens flat as earnings deluge looms

NEW YORK (Reuters) - U.S. stocks opened flat on Monday as investors found few reasons to keep buying following a strong rally last week and ahead of a heavy week of corporate earnings. The Dow Jones industrial average rose 12 points or 0.07 percent, to 16,420.54, the S&P 500 gained 0.89 points or 0.05 percent, to 1,865.74 and the Nasdaq Composite added 7.013 points or 0.17 percent, to 4,102.529. (Reporting by Ryan Vlastelica)  More »

AstraZeneca cancer pipeline seen as draw for Pfizer

By Ben Hirschler LONDON (Reuters) - Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise. In addition to adding promising - though still risky - experimental medicines known as immunotherapies that boost the body's immune system to fight tumors, acquiring AstraZeneca could also generate significant cost savings, according to industry analysts. As a result, a deal at around a 25 percent premium to the current share price funded by cash, cheap debt and some stock could boost Pfizer earnings immediately, they believe. Both companies have declined to comment on a report in the Sunday Times, which cited senior investment bankers and industry sources saying that Pfizer approached the British pharmaceuticals group about a deal.  More »

Health care site flagged in Heartbleed review

WASHINGTON (AP) — People who have accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the confounding Heartbleed Internet security flaw.  More »

ER trips for kids' pain and coughs often end with codeine

By Andrew M. Seaman NEW YORK (Reuters Health) - Despite recommendations against the use of codeine in children, a new study found many emergency room doctors still give the potentially dangerous opioid to kids, such as for pain and coughs. While...  More »

Wall Street opens flat as earnings deluge looms

NEW YORK (Reuters) - U.S. stocks opened flat on Monday as investors found few reasons to keep buying following a strong rally last week and ahead of a heavy week of corporate earnings. The Dow Jones industrial average rose 12 points or 0.07 percen...  More »

Futures flat as investors await earnings onslaught

By Ryan Vlastelica NEW YORK (Reuters) - U.S. stock index futures pointed to a flat open on Monday as investors found few reasons to keep buying following a strong rally last week and ahead of a heavy week of corporate earnings. * The S&P 500 <...  More »

Sarepta to start new trials on muscle disorder drug, shares jump

(Reuters) - Sarepta Therapeutics Inc will start new trials of its experimental muscle disorder drug, nearly five months after the U.S. Food and Drug Administration said data from a previous study may not be sufficient to support the drug's app...  More »

Futures edge up as investors await earnings onslaught

By Ryan Vlastelica NEW YORK (Reuters) - U.S. stock index futures were very slightly higher on Monday as investors found few reasons to keep buying following a strong rally last week and ahead of a heavy week of corporate earnings releases. The S...  More »

Sarepta to start new trials on muscle disorder drug

(Reuters) - Sarepta Therapeutics Inc said it would start new trials to revive the chance of approval for its experimental muscle disorder drug after the U.S. Food and Drug Administration advised the company to submit new safety and efficacy data. ...  More »

of 51

Follow Yahoo Health on and become a fan on

Sponsored Links

Medical Articles | jwatch.org
Medical Articles | jwatch.org
Free Email Alerts in 13 Specialties & 20 Medical Topics. Sign Up Today.
jwatch.org
Kaiser Permanente® | medicare.kaiserpermanente.org
Kaiser Permanente® | medicare.kaiserpermanente.org
Explore Your Medicare Health Plan Options in Washington DC. Get Info!
medicare.kaiserpermanente.org
NEJM - Official Site | NEJM.org
NEJM - Official Site | NEJM.org
The Latest Medical Research from The New England Journal of Medicine
NEJM.org
Follow @YahooHealth on
Health Search
 

Check your Symptoms

Discover possible causes based on your symptoms

 

Search for Treatment

 

Search for Drugs